The pathogen C. diff - the most common cause of health care-associated infectious diarrhea - can use a compound that kills ...

Tinidazole was approved by the FDA in May 2004 for the treatment of trichomoniasis, giardiasis, amebiasis, and amebic liver abscess.

It may take up to two weeks for a bout of C. diff to respond to treatment and for diarrhea to clear up. In the interim, while ...

A synthetic microbiome therapy, tested in mice, holds promise as a new treatment for C. difficile, a notoriously difficult-to-treat bacterial infection, according to a team of researchers.

New insights into a "friendly virus" that could pave the way for cutting-edge treatments for the potentially fatal superbug C ...

The team developed the treatment for Clostridioides difficile, or C. difficile, a bacterium that can cause severe diarrhea, abdominal pain and colon inflammation. C. difficile can overgrow when ...

difficile treatment. Oral FZ002 is a live yeast genetically modified to express a tetraspecific anti-toxin for C. difficile in the gastrointestinal (GI) tract. FZ002 is a first-in-class multi ...

Clostridioides difficile infection is a major healthcare-associated infection, causing significant morbidity and mortality, ...